Continuing efforts to obtain continuous delivery of levodopa

Movement Disorders

Volumn 26, Issue 12, 2011, Pages 2149-2150

  Obeso, Jose A ^a   Olanow, Warren ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; IPX 066; LEVODOPA; UNCLASSIFIED DRUG;

CONTINUOUS INFUSION; DOPAMINE BRAIN LEVEL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DYSKINESIA; EDITORIAL; HUMAN; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DOPAMINE AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 80055100390     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23996     Document Type: Editorial

References (13)

1. Onn SP, West AR, Grace AA. Dopamine-mediated regulation of striatal neuronal and network interactions. Trends Neurosci. 2000; 23(10 Suppl): S48-S56.
2. Obeso JA, Grandas F, Herrero MT, Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci. 1994; 6: 889-899.
3. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006; 5: 677-687.
4. Rosin AJ, Devereux D, Eng N, Calne DB. Parkinsonism with 'on-off' phenomena. Intravenous treatment with levodopa after major abdominal surgery. Arch Neurol. 1979; 36: 32-34.
5. Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol. 1987; 22: 475-479.
6. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Quinn N, Marsden CD, Parkes JD. Lancet. 1982; 2: 412-415.
7. Obeso JA, Luquin MR, Martínez-Lage JM. Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease. Lancet. 1986; 1(8479): 467-470.
8. Stibe C, Lees A, Stern G. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Lancet. 1987; 1: 871.
9. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease--long-term experience. Acta Neurol Scand. 2001; 104: 343-348.
10. Horowski R, Marsden CD, Obeso JA. Continuous dopaminergic stimulation: state of the art and outlook. J Neural Transm Suppl. 1988; 27: 249-252.
11. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009; 66: 563-570.
12. Deleu D, Jacques M, Michotte Y, Ebinger G. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. Neurology. 1989; 39(11 Suppl 2): 88-92.
13. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010; 68: 18-27.